CXCR1 and peripheral neuropathy: Starting from these concepts, we investigated whether the inhibition of chemokine receptors CXCR1/2 by our compound DF2755A (Lopes et al., 2016) could reduce peripheral neuropathy in a rat model of CYP-induced non-Hunner IC/BPS, which is commonly characterized by the absence of inflammatory infiltrate (Augé et al., 2020).